Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease

Adv Neurol. 1996;69:541-4.
No abstract available

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antiparkinson Agents / adverse effects*
  • Antiparkinson Agents / therapeutic use
  • Delusions / drug therapy*
  • Delusions / etiology
  • Female
  • Hallucinations / drug therapy*
  • Hallucinations / etiology
  • Humans
  • Levodopa / adverse effects*
  • Levodopa / therapeutic use
  • Male
  • Middle Aged
  • Ondansetron / adverse effects
  • Ondansetron / therapeutic use*
  • Parkinson Disease / complications*
  • Parkinson Disease / drug therapy
  • Parkinson Disease / psychology
  • Serotonin Antagonists / adverse effects
  • Serotonin Antagonists / therapeutic use*

Substances

  • Antiparkinson Agents
  • Serotonin Antagonists
  • Levodopa
  • Ondansetron